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Abstract  
Aim: We aimed to investigate the effects of diabetes treatment modalities on haematological 
parameters and leukocyte formula in patients with type 2 diabetes mellitus. 
Materials and Methods: The study included 102 patients with type 2 diabetes, out of which 51 
receiving insulin treatment and 51 receiving oral antidiabetics (OAD). Hemogram data of insulin and 
OAD treated groups were compared. 
Results HbA1c levels were 11.12 ± 2.09 mg/dl in insulin group and 7.94 ± 2.1 mg/dl in OAD group 
p=0.001. Platelet counts were 27866.67 ± 77693 10
9
/L before treatment and 258941.18 ± 69068.2 
10
9
/L in OAD group at six months, p: 0.015 whereas; 293011.76 ± 73711.21 10
9
/L before treatment 
and 289492.86 ± 82631.49 10
9
/L in insulin group at six months p: 0.821. Monocyte counts were 
0.47 ± 0.12 10
9
/L before the treatment and 0.57 ± 0.12 10
9
/L in mix insulin therapy subgroup at six 
months, p:0.004; monocyte percentage was % 6.11 ± 1.74 before the treatment and %7.51 ± 2.57 
in mix insulin subgroup at six months p:0.039;  Basophiles counts were 0.1 ±  0.02 10
9
/L before 
treatment and 0.09 ± 0.04 10
9
/L in intensive insulin therapy subgroup at six months, p: 0.005; 
Lymphocyte and basophils counts were significantly decreased at six months insulin treatment as 
compared to the pretreatment values.  
Conclusion: This study showed that, glucose control effects; blood indices HbA1C, basophiles, 
eosinophils, platelets and lymphocytes counts. 
 
 
 
Introduction 
Diabetes Mellitus (DM), is a multisystemic 
disease characterized by high blood sugar levels 
causing acute and chronic complications. High blood 
sugar levels caueses these complications. Diabetes 
mellitus is known to cause anemia of chronic disease, 
erythrocyte, leukocyte and platelet dysfunction [1-4]. 
Oral antidiabetics and insulins are used for the 
treatment of type 2 DM for many years. These 
treatment models can be applied separately or in 
combination. The aim of the treatment is reduction of 
diabetic complications by providing blood sugar 
regulation and suppression of chronic inflammatory 
process. 
The effects of the various medical treatment 
modalities for patients with type 2 DM upon the 
hematological parameters have been analyzed, 
 showing mainly no significant side effects, the most 
common side effects being allergic reactions. The 
increase in the peripheral blood eosinophils, 
basophils, and leukocyte counts seen in allergic 
reactions is also seen in chronic inflammatory 
processes, but the latter can be improved by 
regulation of blood sugar. This regulation also reduces 
the number of inflammatory cells in the peripheral 
blood.  
The aim of our study was to evaluate the 
effects of glucose control on the hematological 
parameters in the study population.  
 
Materials and Methods 
We have performed a retrospective analysis 
of the data of 102 patients with type 2 diabetes 
mellitus, which have been followed-up at the Diabetes 
Polyclinic of our hospital for at least 6 months. The 
diagnosis of type 2 diabetes was based upon the 
diagnostic criteria of the American Diabetes 
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Association (ADA) from 2010. Venous blood samples 
were obtained from subjects for hemogram studies. 
The patients treated with insulin were divided into 
three subgroups: patients receiving conventional 
insulin therapy regime (short/intermediate acting 
insulin mixture 2 times a day), patients on intensive 
insulin regime (short-acting insulin 3 times a day and 
basal long-acting insulin) and patients using OAD in 
combination with basal insulin. The patients using oral 
antidiabetic therapy were also divided into 3 
subgroups: patients using metformin, patients using 
metformin and sulfonylurea and patients using 
metformin and DPP4 analogues. Haematologic 
parameters and HbA1c levels were measured at the 
initiation of the therapy and after 3 and 6 months  
Table 1: Distributions of the demographic and hematological 
parameters according to insulin and OAD groups. 
 Insulin (n=51) OAD (n=51) 
1p 
Age (year) 55.10 ± 10.86 53.51 ± 10.10 0.446 
Gender  (male) 22 (43.1) 26 (51.0) 0.552 
DM duration (month) 117.45 ± 84.94 43.31 ± 45.96 <0.001 
Hba1c 
Pre-Treatment 11.12 ± 2.09 7.94 ± 2.11 <0.001 
Post-Treat. 3rd Month 9.17 ± 2.01 6.78 ± 1.25 <0.001 
Post-Treat. 6th Month 8.68 ± 1.95 7.13 ± 1.10 <0.001 
2p <0.001 
a,b 0.001 a,b 
 3p <0.001 
WBC 
Pre-Treatment 8072.55 ± 2050.76 8200.00 ± 2068.82 0.755 
Post-Treat. 3rd Month 8410.00 ± 2033.62 8050.98 ± 2034.44 0.377 
Post-Treat. 6th Month 8442.86 ± 2460.14 7805.88 ± 1728.86 0.147 
2p 0.192 0.320 
 3p 0.444 
Hb 
Pre-Treatment 13.02 ± 1.75 13.36 ± 1.63 0.312 
Post-Treat. 3rd Month 12.98 ± 1.53 13.30 ± 1.57 0.305 
Post-Treat. 6th Month 12.85 ± 1.56 13.21 ± 1.39 0.256 
2p 0.985 0.663 
 3p 0.166 
Plt 
Pre-Treatment 293011.76 ± 73711.21 278666.67 ± 77693.93 0.341 
Post-Treat. 3rd Month 285706.00 ± 72484.48 276352.94 ± 75820.00 0.528 
Post-Treat. 6th Month 289492.86 ± 82631.49 258941.18 ± 69068.20 a,b 0.055 
2p 0.821 0.015
 a,c 
 3p 0.287 
MCV 
Pre-Treatment 85.12 ± 6.64 85.12 ± 6.34 1.000 
Post-Treat. 3rd Month 84.88 ± 5.99 84.70 ± 5.90 0.883 
Post-Treat. 6th Month 84.31 ± 6.32 85.37 ± 5.69 0.398 
2p 0.074 0.124 
 3p 0.864 
MPV 
Pre-Treatment 9.59 ± 11.4 8.05 ± 1.27 0.341 
Post-Treat. 3rd Month 9.50 ± 11.59 7.84 ± 1.12 0.311 
Post-Treat. 6th Month 7.87 ± 1.21 8.06 ± 1.17 0.461 
2p 0.291 0.236 
 3p 0.312 
Data were shown as mean ± standard deviation and n (%).  1: Results of the comparison between 
insulin and OAD groups. 2: Results of the comparison among pre-treatment, post-treatment 3rd 
month and post-treatment 6th month measures.  3: Results of the comparison among two groups 
according to alterations of hematologic parameters. a: There was statistically significant difference 
between pre-treatment and post-treatment 3rd month. b: There was statistically significant 
difference between pre-treatment and post-treatment 6th month. c: There was statistically 
significant difference between post-treatment 3rd month and post-treatment 6th month. 
 
In the study we investigated the effect of the 
decrease in HbA1c levels to blood count and 
leukocyte formula in the 6-month treatment period for 
insulin and OAD using groups and also for the 
subgroups Patients are started on insulin therapy 
compared with patients are using oral antidiabetics.  
We investigate the effect of decrease in HbA1c levels 
to blood count and leukocyte formula in 6-month 
treatment period for insulin and OAD using groups 
and also for subgrups. 
All patients were informed for the study and 
signed an informed consent forms for the study. 
Ethics committee approval was taken for the study. 
Statistical analysis was made using computer 
software (SPSS version 15.0, SPSS Inc. Chicago, IL, 
USA). The results of all the parameters of insulin and 
OAD group are given as mean ± standard deviation. 
Samples T test was used to compare the data 
between the two groups. Level of statistical 
significance of the data interpreted with the 'p' value. p 
<0.05 was considered statistically significant.  
Results 
Patients were divided into two groups 
according to using OAD therapy and using insulin 
therapy. The average age of the insulin using group is 
55.1 years, and 53.5 years of OAD using group. The 
distribution of gender is, 22 male/33 female patients (n 
= 55) in insulin using group and 26 male/29 female 
patients (n = 55) in OAD using group.. Duration of 
diabetes was found 117.45 ± 84.94 months in insulin 
using group and 43.31 ± 45.96 months in OAD using 
group (Table 1). 
Table 2: Distributions of the hematological parameters 
according to the insulin and OAD groups. 
 Insulin (n=51) OAD (n=51) 
1
p 
Neu % 
Pre-Treatment 57.59 ± 9.65 58.23 ± 8.65 0.724 
Post-Treat. 3rd Month 57.79 ± 8.76 58.68 ± 7.64 0.590 
Post-Treat. 6th Month 58.79 ± 9.27 57.54 ± 7.2 0.466 
2
p 0.465 0.548 
 3
p 0.895 
Neu 
Pre-Treatment 4.68 ± 1.45 4.78 ± 1.46 0.730 
Post-Treat. 3rd Month 4.91 ± 1.63 4.76 ± 1.50 0.624 
Post-Treat. 6th Month 4.99 ± 1.77 4.52 ± 1.23 0.143 
2
p 0.220 0.413 
 3
p 0.518 
Lym % 
Pre-Treatment 32.56 ± 9.12 32.04 ± 7.26 0.753 
Post-Treat. 3rd Month 32.73 ± 8.41 31.64 ± 7.25 0.486 
Post-Treat. 6th Month 31.35 ± 8.35 32.82 ± 7.18 0.365 
2
p 0.807 0.438 
 3
p 0.959 
Lym 
Pre-Treatment 2.72 ± 0.99 2.69 ± 1.01 0.905 
Post-Treat. 3rd Month 2.74 ± 0.92 2.61 ± 0.98 0.486 
Post-Treat. 6th Month 2.60 ± 0.98 2.62 ± 0.88 0.935 
2
p 0.597 0.631 
 3
p 0.816 
Mono % 
Pre-Treatment 6.57 ± 2.35 7.01 ± 2.33 0.343 
Post-Treat. 3rd Month 6.55 ± 2.34 6.70 ± 2.62 0.756 
Post-Treat. 6th Month 6.92 ± 2.56 6.75 ± 1.87 0.710 
2
p 0.719 0.496 
 3
p 0.906 
Mono 
Pre-Treatment 0.50 ± 0.16 0.58 ± 0.24 0.069 
Post-Treat. 3rd Month 0.54 ± 0.19 0.52 ± 0.2 0.601 
Post-Treat. 6th Month 0.55 ± 0.16 0.53 ± 0.19 0.507 
2
p 0.206 0.165 
 3
p 0.985 
Eos % 
Pre-Treatment 2.24 ± 1.6 2.38 ± 2.08 0.876 
Post-Treat. 3rd Month 2.10 ± 1.28 1.93 ± 1.27 0.508 
Post-Treat. 6th Month 2.10 ± 1.44 2.04 ± 1.35 0.831 
2
p 0.400 0.277 
 3
p 0.550 
Eos 
Pre-Treatment 0.18 ± 0.13 0.20 ± 0.22 0.870 
Post-Treat. 3rd Month 0.18 ± 0.12 0.16 ± 0.12 0.479 
Post-Treat. 6th Month 0.18 ± 0.12 0.17 ± 0.12 0.496 
2
p 0.913 0.327 
 3
p 0.468 
Baso% 
Pre-Treatment 0.90 ± 0.38 0.88 ± 0.39 0.776 
Post-Treat. 3rd Month 0.83 ± 0.29 0.9 ± 0.41 0.328 
Post-Treat. 6th Month 0.84 ± 0.28 0.88 ± 0.34 0.611 
2
p 0.266 0.843 
 3
p 0.667 
Baso 
Pre-Treatment 0.08 ± 0.04 0.08 ± 0.06 0.551 
Post-Treat. 3rd Month 0.07 ± 0.05 0.08 ± 0.06 0.535 
Post-Treat. 6th Month 0.08 ± 0.04 0.07 ± 0.05 0.348 
2
p 0.225 0.741 
 3
p 0.733 
Data were shown as mean ±standard deviation.
 1
: Results of the comparison between 
insulin and OAD groups. 
2
: Results of the comparison among pre-treatment, post-
treatment 3rd month and post-treatment 6th month measures. 
 3
: Results of the 
comparison among two groups according to alterations of hematologic parameters. 
Hematological parameters such as platelet 
and white blood cell count, hemoglobin, hematocrite, 
mean corpuscular volume (MCV), mean platelet 
volume (MPV), white blood cell formulas (neutrophils, 
lymphocytes, eosinophils, basophils, monocytes 
percentages) and HbA1c levels were examined in 
Varım et al. Glucose Control on Hematological Indices in Patients with Diabetes Mellitus 
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both groups. The start of study, 3 and 6 months, these 
parameters and HbA1c levels were recorded. 
Changes in these parameters and HbA1c levels were 
assessed between insulin and OAD using group and 
as well as its subgroups. HbA1c levels were %11.12 ± 
2.09 mg/dl in insulin group and %7.94 ± 2.1 in OAD 
group p = 0.001. Platelet counts were 27866.67 ± 
77693 10
9
/L before treatment and 258941.18 ± 
69068.2 10
9
/L in OAD using group at six months, p: 
0.015 whereas; 293011.76 ± 73711.21 109/L before 
treatment and 289492.86 ± 82631.49 10
9
/L, in insulin 
theraphy group at six months p: 0.821 (Table 1 and 
2). 
Table 3: Distributions of the demographic and hematological 
parameters according to the insulin subgroups. 
 
Mix insulin 
 (n=20) 
 
Intensive insulin 
 (n=19) 
 
OAD+Basal 
insulin 
 (n=12) 
1
p 
Age (year) 55.5 ± 8.38 53.37 ± 13.01 57.17 ± 11.3 0.633 
Gender  (male) 9 (45) 8 (42.1) 5 (41.7) 0.977 
DM duration (month) 126 ± 76.94 110 ± 106.26 115 ± 62.14 0.841 
Hba1c 
Pre-Treatment 11.16 ± 1.86 11.68 ± 2.04 10.15 ± 2,35 0.137 
Post-Treat. 3rd 
Month 
9.31 ± 2.05 9.55 ± 2.27 8.34 ± 1.31 0.279 
Post-Treat. 6th 
Month 
8.45 ± 1.6
 
9.49 ± 2.28
 
7.88 ± 1.52
 
0.106 
2
p 0.010 
b 
0.024 
b 
0.005 
b 
 3
p 0.100 
WBC 
Pre-Treatment 7970 ± 1522.84 8810.53 ± 2459.43 7075 ± 1779.75 0.066 
Post-Treat. 3rd 
Month 
8705 ± 2425.41 8678.95 ± 1617.12 7409.09 ± 1722.47 0.183 
Post-Treat. 6th 
Month 
8131.25 ± 2448.6 9426.67 ± 2449.92 7554.55 ± 2223.23 0.129 
2
p 0.161 0.298 0.631 
 3
p 0.079 
Hb 
Pre-Treatment 12.86 ± 1.67 13.25 ± 1.91 12,.3 ± 1.75 0.778 
Post-Treat. 3rd 
Month 
12.91 ± 1.27 13.15 ± 1.95 12.84 ± 1.22 0.836 
Post-Treat. 6th 
Month 
12.41±1.5 13.39 ± 1.8 12.72 ± 1.13 0.217 
2
p 0.567 0.630 0.801 
 3
p 0.451 
Plt 
Pre-Treatment 294000 ± 62839 300263.2 ± 72371.6 279883.3 ± 95000.8 0.760 
Post-Treat. 3rd 
Month 
284300 ± 65384 294789.5 ± 72900.7 272572.7 ± 87780.5 0.725 
Post-Treat. 6th 
Month 
290375 ± 54585.6 305600 ± 92041.8 266245.5 ± 103344.2 0.497 
2
p 0.781 0.199 0.406 
 3
p 0.806 
MCV 
Pre-Treatment 85.81 ± 7.59 85.05 ± 5.52 84.07 ± 7.01 0.779 
Post-Treat. 3rd 
Month 
84.97 ± 7.05
 
84.83 ± 5.79 84.78 ± 4.57 0.996 
Post-Treat. 6th 
Month 
84.38 ± 6.56 84.23 ± 7.45 84.32 ± 4.65 0.998 
2
p 0.037 
a 
0.279 0.758 
 3
p 0.933 
MPV 
Pre-Treatment 8.21 ± 1.29 11.74 ± 18.58 8.49 ± 3.2 0.591 
Post-Treat. 3rd 
Month 
7.88 ± 0.96 11.81 ± 18.77 8.46 ± 2.5 0.550 
Post-Treat. 6th 
Month 
7.76 ± 0.99 7.78 ± 1.26 8.16 ± 1.46 0.661 
2
p 0.056 0.350 0.775 
 3
p 0.556 
Data were shown as mean ±standard deviation and n (%). 
 1
: Results of the comparison 
among groups. 
2
: Results of the comparison among pre-treatment, post-treatment 3rd 
month and post-treatment 6th month measures. 
 3
: Results of the comparison among three 
groups according to alterations of hematologic parameters. 
a
: There was statistically 
significant difference between pre-treatment and post-treatment 3rd month..
 b
: There was 
statistically significant difference between pre-treatment and post-treatment 6th month. 
 
 
Insulin treatment group was divided into 3 
subgroups. These subgroups consisted of patients 
initiated on mixed insulin therapy, patients started on 
intensive insulin therapy and patients using OAD 
therapy in combination with basal insulin. 
Hematological parameters, white blood cell formulas 
and HbA1c levels were examined in both subgroups. 
HbA1c levels were %11.16 ± 1.86 before treatment 
and % 8.45 ± 1.6 in mix insulin therapy subgroup at 
six months p: 0.010; HbA1c levels were %11.68 ± 
2.04 before treatment and %9.49 ± 2.28 in intensive 
insulin therapy subgroup at six months p = 0.024; 
HbA1c  levels  were %10.15 ± 2.35  before treatment 
and % 7.88 ± 1.52 in OAD therapy and added basal 
insulin subgroup at six months p = 0.005.   
Table 4: Distributions of the hematological parameters 
according to the insulin subgroups. 
 
Mix insulin 
(n=20) 
Intensive 
insulin 
 (n=19) 
OAD+Basal 
insulin 
 (n=12) 
1
p 
Neu 
% 
Pre-Treatment 57.17 ± 10.78 56.74 ± 10.03 59.65 ± 7.19 0.701 
Post-Treat. 3rd Month 56.98 ± 9.82 57.53 ± 7.31 59.73 ± 9.54 0.703 
Post-Treat. 6th Month 55.58 ± 10.32 59.27 ± 8.03 62.81 ± 8.24 0.133 
2
p 0.839 0.162 0.195 
 3
p 0.428 
Neu 
Pre-Treatment 4.63 ± 1.38 5.04 ± 1.66 4.21 ± 1.15 0.301 
Post-Treat. 3rd Month 5.07 ± 2.15 5.01 ± 1.17 4.45 ± 1.19 0.568 
Post-Treat. 6th Month 4.53 ± 1.79 5.6 ± 1.68 4.82 ± 1.79 0.230 
2
p 0.303 0.125 0.354 
 3
p 0.389 
Lym 
% 
Pre-Treatment 33.99 ± 9.08 32.86 ± 9.82 29.73 ± 8.15 0.443 
Post-Treat. 3rd Month 33.74 ± 8.67 33.36 ± 6.95 29.83 ± 10.26 0.436 
Post-Treat. 6th Month 33.63 ± 7.72 32.05 ± 8.68 27.09 ± 7.85 0.124 
2
p 0.993 0.984 0.226 
 3
p 0.209 
Lym 
Pre-Treatment 2.68 ± 0.82 3.14 ± 1.14 2.13 ± 0.73
 
0.020 
f 
Post-Treat. 3rd Month 2.88 ± 0.94 2.91 ± 0.88 2.22 ± 0.83 0.099 
Post-Treat. 6th Month 2.59 ± 0.71 3.03 ± 1.22 2.02 ± 0.66
 
0.029 
f 
2
p 0.108 0.336 0.385 
 3
p 0.019 
i 
Mono 
% 
Pre-Treatment 6.11 ± 1.74 6.57 ± 3.08 7.3 ± 1.78 0.394 
Post-Treat. 3rd Month 6.49 ± 1.89 6.15 ± 2.6 7.35 ± 2.64 0.409 
Post-Treat. 6th Month 7.51 ± 2.57
 
5.95 ± 2 7.38 ± 3.03 0.188 
2
p 0.039 
b 
0.178 0.991 
 3
p 0.571 
Mono 
Pre-Treatment 0.47 ± 0.12 0.54 ± 0.21 0.49 ± 0.11 0.403 
Post-Treat. 3rd Month 0.56 ± 0.17
 
0.52 ± 0.2 0.54 ± 0.2 0.857 
Post-Treat. 6th Month 0.57 ± 0.12
 
0.55 ± 0.15 0.53 ± 0.23 0.810 
2
p 0.004 
a.b 
0.868 0.735 
 3
p 0.865 
Eos 
% 
Pre-Treatment 2.15 ± 1.76 2.27 ± 1.6 2.33 ± 1.44 0.949 
Post-Treat. 3rd Month 1.94 ± 0.94 2.23 ± 1.5 2.17 ± 1.5 0.774 
Post-Treat. 6th Month 2.27 ± 1.89 1.99 ± 1.18
 
1.99 ± 0.99 0.828 
2
p 0.605 0.042 
c 
0.687 
 3
p 0.944 
Eos 
Pre-Treatment 0.16 ± 0.12 0.2 ± 0.13 0.18 ± 0.14 0.635 
Post-Treat. 3rd Month 0.17 ± 0.08 0.18 ± 0.11 0.16 ± 0.15 0.830 
Post-Treat. 6th Month 0.19 ± 0.13 0.19 ± 0.12 0.15 ± 0.09 0.550 
2
p 0.691 0.685 0.574 
 3
p 0.645 
Baso
% 
Pre-Treatment 0.89 ± 0.38 0.85 ± 0.34 0.99 ± 0.44 0.601 
Post-Treat. 3rd Month 0.85 ± 0.3 0.76 ± 0.3 0.92 ± 0.26 0.331 
Post-Treat. 6th Month 0.91 ± 0.24 0.83 ± 0.3 0.76±0.33 0.446 
2
p 0.737 0.239 0.143 
 3
p 0.759 
Baso 
Pre-Treatment 0.08 ± 0.04 0.1 ± 0.02 0.08 ± 0.05 0.212 
Post-Treat. 3rd Month 0.08 ± 0.04 0.06 ± 0.05
 
0.08 ± 0.04 0.525 
Post-Treat. 6th Month 0.09 ± 0.03 0.09 ± 0.04
 
0.06 ± 0.05
 0.029 
e,f 
2
p 0.167 0.005 
a.c 
0.092 
 3
p 0.554 
Data were shown as mean ±standard deviation and n (%).
 1
: Results of the comparison 
among groups. 
2
: Results of the comparison among pre-treatment, post-treatment 3rd 
month and post-treatment 6th month measures. 
 3
: Results of the comparison among three 
groups according to alterations of hematologic parameters. 
a
: There was statistically 
significant difference between pre-treatment and post-treatment 3rd month..
 b
: There was 
statistically significant difference between pre-treatment and post-treatment 6th month.. 
c
: 
There was statistically significant difference between post-treatment 3rd month and post-
treatment 6th month.
e
: There was statistically significant difference between group 1 and 
group 3. 
f
: There was statistically significant difference between group 2 and group 3. 
i
: 
There was statistically significant difference between group 2 and group 3. 
 
Monocyte counts were 0.47 ± 0.12 10
9
/L 
before the treatment and 0.57 ± 0.12 10
9
/L in mix 
insulin therapy subgroup at six months, p = 0.004; 
monocyte percentage was % 6.11 ± 1.74 before the 
treatment and %7.51 ± 2.57 in mix insulin therapy 
subgroup at six months p = 0.039; Basophils counts 
were 0.1 ± 0.02 10
9
/L before treatment and 0.09 ± 
0.04 10
9
/L in intensive insulin therapy subgroup at six 
months, p: 0.005; Eosinophil percentage  was  %2.27  
±  1.6  before treatment and %1.99 ± 1.18 in intensive 
insulin using subgroup at six months, p: 0.042. 
Lymphocyte and basophils counts were significantly 
decreased at six months insulin treatment as 
compared to the pretreatment values. There was no 
statistically significant difference found in other 
parameters (Table 3 and 4). 
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Table 5: Distributions of the demographic and hematological 
parameters according to the OAD subgroups. 
 
Metformin 
(n=13)   
Metformin + 
sulfonylurea 
(n=23) 
 
Metformin + 
DPP4 analogues 
 (n=15) 
 
1
p 
Age (year) 50.23 ± 9.19 53.3 ± 9.87 56.67 ± 10.88 0.245 
Gender  (male) 4 (30.8) 13 (56.5) 9 (60) 0.235 
DM duration (month) 17.92 ± 20.62 54.17 ± 54.13 47.54 ± 40.26 0.077 
Hba1c 
Pre-Treatment 8.17 ± 2.59 7.88 ± 1.86 7.85 ± 2.15 0.910 
Post-Treat. 3rd 
Month 
5.93 ± 0.8
 
7.42 ± 1.35
 
6.54 ± 0.85
 
0.001 
e,f 
Post-Treat. 6th 
Month 
6.72 ± 0.92 7.32 ± 1.16 7.2 ± 1.12 0.286 
2
p 0.025 
a 
0.227 0.071 
 3
p 0.243 
WBC 
Pre-Treatment 8130.77 ± 2756.32 8386.96 ± 1704.35 7973.33 ± 2022.89 0.832 
Post-Treat. 3rd 
Month 
7923.08 ± 3016.39 8321.74 ± 1856.43 7746.67 ± 1154.41 0.681 
Post-Treat. 6th 
Month 
7430.77 ± 2144.13 8052.17 ± 1621.13 7753.33 ± 1539.88 0.588 
2
p 0.460 0.654 0.869 
 3
p 0.654 
Hb 
Pre-Treatment 13.59 ± 1.76 13.36 ± 1.5 13.17 ± 1.8 0.795 
Post-Treat. 3rd 
Month 
13.21 ± 1.16 13.39 ± 1.57 13.24 ± 1.94 0.933 
Post-Treat. 6th 
Month 
13.13 ± 1.18 12.95 ± 1.09 13.66 ± 1.88 0.309 
2
p 0.075 0.075 0.493 
 3
p 0.963 
Plt 
Pre-Treatment 280923.1 ± 79898.3 278739.1 ± 76384.9 276600 ± 83117.7 0.990 
Post-Treat. 3rd 
Month 
274615.4 ± 68476.9 283695.7 ± 86306.2 266600 ± 67921.0 0.797 
Post-Treat. 6th 
Month 
265230.8 ± 63989.8 262260.9 ± 72357.8 248400 ± 71596.9 0.782 
2
p 0.333 0.193 0.164 
 3
p 0.883 
MCV 
Pre-Treatment 84.56 ± 8.41 84.84 ± 6.01 86.03 ± 4.99 0.803 
Post-Treat. 3rd 
Month 
84.5 ± 7.63 84.42 ± 5.02 85.31 ± 5.84 0.895 
Post-Treat. 6th 
Month 
84.92 ± 6.71 85.03 ± 5.2 86.28 ± 5.78 0.768 
2
p 0.766 0.448 0.322 
 3
p 0.819 
MPV 
Pre-Treatment 8.19 ± 1.12 8.21 ± 1.53 7.69 ± 0.89 0.421 
Post-Treat. 3rd 
Month 
7.99 ± 0.97 7.91 ± 1.32 7.59 ± 0.93 0.604 
Post-Treat. 6th 
Month 
8.39 ± 1.55 7.87 ± 0.94 8.06 ± 1.12 0.439 
2
p 0.443 0.184 0.153 
 3
p 0.579 
Data were shown as mean ±standard deviation and n (%).
 1
: Results of the comparison among groups. 
2
: 
Results of the comparison among pre-treatment, post-treatment 3rd month and post-treatment 6th month 
measures. 
 3
: Results of the comparison among three groups according to alterations of hematologic 
parameters. 
a
: There was statistically significant difference between pre-treatment and post-treatment 3rd 
month. 
e
: There was statistically significant difference between group 1 and group 3. 
f
: There was statistically 
significant difference between group 2 and group 3. 
 
The group receiving oral antidiabetic therapy 
was divided into 3 subgroups. These subgroups 
consisted of patients using only metformin, patients 
using metformin + sulfonylurea and patients using 
metformin + DPP4 analogues Hematological 
parameters, white blood cell formulas and HbA1c 
levels were examined in both subgroups. There was 
no statistically significant difference in both 
parameters before treatment and at six months (Table 
5 and 6). 
 
Discussion 
The results of this study showed that glucose 
control significantly lowers HbA1c levels together with 
blood sugar regulation. On the other hand causes a 
significant decrease in the number of basophils, 
eosinophils, platelets, lymphocytes. These findings 
are very important. Significant numerical and 
proportional decrease in the number of basophils, 
eosinophils, platelets, lymphocytes suggest that 
regulation of blood sugar has an anti-inflammatory 
activity. Diabetic patients are more prone to certain 
infections than those without DM. Regulation of blood 
glucose increases the anti-inflammatory activity and 
reduces predisposition to infections. However, in vitro 
and in vivo more studies are needed for further 
investigation.  
Diabetes Mellitus is a chronic metabolic 
disorder due to insulin deficiency or defects on the 
effect of insulin and requiring a continuous medical 
care. There is disturbance in body metabolism and 
energy utilization from carbohydrates, fats and 
proteins insufficiently [5]. 
 
Table 6: Distributions of the hematological parameters 
according to the OAD subgroups. 
 
 
Metformin 
(n=13) 
 
 
Metformin + 
sulfonylurea 
 (n=23) 
 
 
Metformin+ 
DPP4 
analogues 
 (n=15) 
1
p 
Neu % 
Pre-Treatment 57.06 ± 7.06 57.35 8 .26 60.6 ± 10.44 0.458 
Post-Treat. 3rd 
Month 
59.19 ± 10.06 58.62 ± 7.71 58.32 ± 5.28 0.957 
Post-Treat. 6th 
Month 
56.81 ± 6.93 57.39 ± 8.39 58.41 ± 5.64 0.840 
2
p 0.495 0.583 0.499 
 3
p 0.803 
Neu 
Pre-Treatment 4.61 ± 1.6 4.82 ± 1.2 4.87 ± 1.77 0.886 
Post-Treat. 3rd 
Month 
4.75 ± 2.29 4.91 ± 1.39 4.52 ± 0.66 0.740 
Post-Treat. 6th 
Month 
4.24 ± 1.4 4.65 ± 1.3 4.57 ± 1 0.626 
2
p 0.576 0.638 0.668 
 3
p 0.787 
Lym % 
Pre-Treatment 32.92 ± 6.28 31.97 ± 8.16 31.34 ± 6.95 0.857 
Post-Treat. 3rd 
Month 
31.32 ± 9.25 31.98 ± 7.6 31.39 ± 4.82 0.955 
Post-Treat. 6th 
Month 
33.29 ± 6.91 33.43 ± 8.43 31.48 ± 5.36 0.698 
2
p 0.600 0.450 0.976 
 3
p 0.892 
Lym 
Pre-Treatment 2.94 ± 1.52 2.67 ± 0.86 2.5 ± 0.62 0.536 
Post-Treat. 3rd 
Month 
2.74 ± 1.53 2.65 ± 0.78 2.45 ± 0.62 0.720 
Post-Treat. 6th 
Month 
2.79 ± 1.42 2.65 ± 0.67 2.41 ± 0.52 0.531 
2
p 0.546 0.986 0.874 
 3
p 0.597 
Mono % 
Pre-Treatment 6.95 ± 1.94 7.35 ± 2.75 6.56 ± 1.95 0.600 
Post-Treat. 3rd 
Month 
6.74 ± 2.18 6.51 ± 3.17 6.96 ± 2.11 0.879 
Post-Treat. 6th 
Month 
7.18 ± 1.92 6.53 ± 1.97 6.7 ± 1.74 0.615 
2
p 0.541 0.171 0.697 
 3
p 0.959 
Mono 
Pre-Treatment 0.61 ± 0.3 0.6 ± 0.26 0.51 ± 0.15 0.437 
Post-Treat. 3rd 
Month 
0.49 ± 0.16
 
0.53 ± 0.25 0.52 ± 0.16 0.866 
Post-Treat. 6th 
Month 
0.52 ± 0.17
 
0.53 ± 0.21 0.52 ± 0.18 0.985 
2
p 0.300 0.296 0.938 
 3
p 0.790 
Eos % 
Pre-Treatment 2.16 ± 1.41 2 ± 1.37 2.49 ± 1.94 0.641 
Post-Treat. 3rd 
Month 
1.83 ± 1.44 1.64 ± 0.82 2.44 ± 1.58 0.165 
Post-Treat. 6th 
Month 
1.8 ± 1.09 1.63 ± 0.74 2.84 ± 1.89
 
0.018 
f 
2
p 0.257 0.226 0.449 
 3
p 0.118 
Eos 
Pre-Treatment 0.17 ± 0.11 0.16 ± 0.13 0.2 ± 0.18 0.731 
Post-Treat. 3rd 
Month 
0.14 ± 0.1 0.14 ± 0.08 0.2 ± 0.16 0.219 
Post-Treat. 6th 
Month 
0.14 ± 0.09 0.13 ± 0.08 0.23 ± 0.16
 
0.032 
f 
2
p 0.241 0.290 0.529 
 3
p 0.184 
Baso% 
Pre-Treatment 0.93 ± 0.31 0.91 ± 0.45 0.77 ± 0.34 0.747 
Post-Treat. 3rd 
Month 
0.94 ± 0.37 0.87 ± 0.47 0.91 ± 0.38 0.904 
Post-Treat. 6th 
Month 
0.93 ± 0.31 0.88 ± 0.39 0.83 ± 0.3 0.729 
2
p 0.995 0.837 0.278 
 3
p 0.740 
Baso 
Pre-Treatment 0.09 ± 0.06 0.07 ± 0.07 0.07 ± 0.05 0.850 
Post-Treat. 3rd 
Month 
0.06 ± 0.07 0.09 ± 0.05 0.07 ± 0.06 0.310 
Post-Treat. 6th 
Month 
0.07 ± 0.05 0.07 ± 0.04 0.07 ± 0.05 0.955 
2
p 0.255 0.269 1.000 
 3
p 0.849 
Data were shown as mean ±standard deviation and n (%).
 1
: Results of the comparison 
among groups. 
2
: Results of the comparison among pre-treatment, post-treatment 3rd 
month and post-treatment 6th month measures. 
 3
: Results of the comparison among three 
groups according to alterations of hematologic parameters. 
f
: There was statistically 
significant difference between group 2 and group 3. 
 
Varım et al. Glucose Control on Hematological Indices in Patients with Diabetes Mellitus 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2014 Mar 15; 2(1):83-88.                                                                                                                                                                               87 
 
The incidence of anemia is increased in 
patients with diabetes. The reason is multifactorial. 
Chronic hyperglycemia causes abnormal red blood 
cells and renal sympathetic denervation is associated 
with oxidative stress and autonomic neuropathy [6]. 
Hypoxic environment occurs in the renal tubulo 
interstitial. The amount of erythropoietin produced by 
the peritubular fibroblasts reduces and becomes 
inappropriate production. The earliest and the most 
important reason of anemia in diabetic patients is 
inappropriately and low erythropoietin levels [1]. 
Systemic inflammation, functional hematinic 
deficiencies, erythropoietin resistance and reduced 
red cell survival also drive anemia in the setting of 
impaired renal compensation [7]. 
Mean platelet volume (MPV Mean Platelet 
Volume), measured by the hematology analyzers, is a 
marker showing platelet function and activation. 
Altered platelet morphology and function can be 
considered as a factor for risk of micro-and 
macrovascular diseases [2, 8].  Large platelets are 
younger and more reactive. Therefore, these platelets 
secrete more serotonin and β-thromboglobulin, 
contain more intense granules and produce more 
thromboxane A2 [9-12]. All of these give rise to a 
procoagulant effect and may cause thrombotic 
vascular complications. It may talk about the 
relationship between changes in platelet function 
especially MPV and diabetic vascular complications 
[2]. 
There are many studies showing the 
relationship between MPV and diabetes mellitus. 
There are studies showing the relationship between 
MPV and level of fasting blood glucose, postprandial 
blood glucose, and impaired fasting glucose and 
HbA1c levels in diabetic peripheral arterial disease. 
MPV values was found increased in all of these 
studies [2, 13-18]. We did not found significant change 
in MPV values but a significant decrease found in 
platelet counts in OAD group at six month. Avoid an 
increase in MPV, falling in platelet counts showed that 
OAD therapy may be effective in preventing vascular 
complications of diabetes mellitus. 
Diabetes mellitus is a chronic inflammatory 
disease. In studies, peripheral blood leukocyte count 
[19], acute phase reactants such as C-reactive protein 
(CRP) [20], interleukin 6 (IL-6) [21], tumor necrosing 
factor α (TNF-α) [22], serum-amyloid A (S-AA) [23, 
24], was found increased in patients with impaired 
fasting glucose or insulin resistance. An inverse 
relationship was shown between HbA1c levels and 
inflammatory cytokine levels in the blood. This chronic 
inflammatory process is is supressed by regulation of 
blood glucose [3]. A prospective study including 
twenty-study meta-analysis showed that number of 
peripheral blood leukocytes, basophils, eosinophils 
and neutrophils increased, no change in the number 
of monocytes in patients with Type 2 DM [4]. We 
found significant difference in the number of 
lymphocytes   (p = 0.029) and basophils (p = 0.029) in 
insulin using group in 6
th
 month. This result shows that 
insulin therapy may be effective in suppressing 
chronic inflammatory process. A statistically significant 
relationship was showed between blood leukocyte 
count and glucose intolerance in the study made by 
Gokulakrishnan K. and et al [25]. 
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